We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Judge Dismisses Teva API Patent Challenge Against Mylan, Sandoz
Judge Dismisses Teva API Patent Challenge Against Mylan, Sandoz
July 26, 2013
A district court judge granted motions to dismiss filed by Mylan and Sandoz after the companies agreed to abstain from using a method of measuring the active pharmaceutical ingredient (API) for multiple sclerosis drug Copaxone that Teva had challenged infringed on four of its patents.